Scroll

prazosin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antihypertensive substances, prazosin derivatives	4209	19216-56-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: prazosin prazosin hydrochloride furazosin prazosin HCl	A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION. Molecular weight: 383.41 Formula: C19H21N5O4 CLOGP: 2.08 LIPINSKI: 0 HAC: 9 HDO: 1 TPSA: 106.95 ALOGS: -2.74 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

prazosin
prazosin hydrochloride
furazosin
prazosin HCl

A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.

Molecular weight: 383.41
Formula: C19H21N5O4
CLOGP: 2.08
LIPINSKI: 0
HAC: 9
HDO: 1
TPSA: 106.95
ALOGS: -2.74
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
5	mg	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	68 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
CL (Clearance)	4.70 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2 hours	Lombardo F, Berellini G, Obach RS
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.49 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
S (Water solubility)	1.40 mg/mL	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
Vd (Volume of distribution)	0.73 L/kg	Lombardo F, Berellini G, Obach RS
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
fu (Fraction unbound in plasma)	0.06 %	Lombardo F, Berellini G, Obach RS

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
June 23, 1976	FDA	PFIZER

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Atrioventricular block first degree	108.13	16.06	37	6505	7236	63475244
Completed suicide	74.30	16.06	83	6459	145590	63336890
Suicidal ideation	53.04	16.06	47	6495	62374	63420106
Toxicity to various agents	51.95	16.06	92	6450	247158	63235322
Unmasking of previously unidentified disease	50.32	16.06	13	6529	963	63481517
Electrocardiogram ST segment elevation	43.26	16.06	16	6526	3911	63478569
Electrocardiogram repolarisation abnormality	41.93	16.06	12	6530	1305	63481175
Sinus bradycardia	41.34	16.06	23	6519	14528	63467952
Norepinephrine increased	41.26	16.06	7	6535	62	63482418
Circulatory collapse	39.81	16.06	26	6516	21912	63460568

Showing 1 to 10 of 51 entries

Previous1 2 3 4 5 6Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Antidepressant drug level above therapeutic	107.26	17.20	20	4898	226	34951787
Analgesic drug level above therapeutic	102.46	17.20	20	4898	293	34951720
Parasomnia	74.33	17.20	16	4902	388	34951625
Priapism	65.06	17.20	25	4893	4969	34947044
Sudden cardiac death	53.53	17.20	20	4898	3681	34948332
Serotonin syndrome	51.25	17.20	33	4885	19900	34932113
Abnormal sleep-related event	50.07	17.20	12	4906	475	34951538
Suicidal behaviour	49.22	17.20	15	4903	1482	34950531
Vasoplegia syndrome	38.08	17.20	13	4905	1843	34950170
Drug interaction	35.80	17.20	90	4828	225856	34726157

Showing 1 to 10 of 31 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Analgesic drug level above therapeutic	96.13	14.11	20	9830	469	79734069
Antidepressant drug level above therapeutic	89.68	14.11	20	9830	656	79733882
Atrioventricular block first degree	88.58	14.11	39	9811	12452	79722086
Completed suicide	78.49	14.11	122	9728	245645	79488893
Parasomnia	76.63	14.11	17	9833	544	79733994
Priapism	70.71	14.11	25	9825	4480	79730058
Sinus bradycardia	67.82	14.11	41	9809	25206	79709332
Sudden cardiac death	49.34	14.11	20	9830	5205	79729333
Posterior reversible encephalopathy syndrome	49.16	14.11	34	9816	26247	79708291
Electrocardiogram QT prolonged	48.84	14.11	58	9792	90328	79644210

Showing 1 to 10 of 76 entries

Previous1 2 3 4 5…8Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	C02CA01	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING Alpha-adrenoreceptor antagonists
ATC	C02LE01	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION Alpha-adrenoreceptor antagonists and diuretics
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:37890	alpha-adrenergic receptor blockaders
CHEBI has role	CHEBI:76779	post-proline endopeptidase inhibitors
FDA EPC	N0000175553	alpha-Adrenergic Blocker
FDA MoA	N0000000099	Adrenergic alpha-Antagonists
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D058668	Adrenergic alpha-1 Receptor Antagonists
MeSH PA	D000317	Adrenergic alpha-Antagonists

Showing 1 to 10 of 14 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Benign prostatic hyperplasia	off-label use	266569009
PTSD related nightmares	off-label use	428687006
Chronic Post Traumatic Stress Disorder with Trauma-related Nightmares	off-label use
End stage renal disease	contraindication	46177005	DOID:784
Narcolepsy	contraindication	60380001	DOID:8986
Cataract surgery	contraindication	110473004
Micturition syncope	contraindication	234168001
Syncope	contraindication	271594007
Intraoperative floppy iris syndrome	contraindication	418801006

Showing 1 to 10 of 10 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.22	Basic
pKa2	0.72	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN	INVERSE AGONIST	Ki	9.70	CHEMBL	IUPHAR
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN	INVERSE AGONIST	Ki	9.68	CHEMBL	IUPHAR
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN	INVERSE AGONIST	Ki	10.40	CHEMBL	IUPHAR
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	5.58	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	7.89	CHEMBL
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN		Ki	9.48	CHEMBL
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.62	CHEMBL
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		IC50	9.07	CHEMBL
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	5.08	CHEMBL
Ribosyldihydronicotinamide dehydrogenase [quinone]	Enzyme	P16083	NQO2_HUMAN		IC50	8.11	CHEMBL

Showing 1 to 10 of 37 entries

Previous1 2 3 4Next

External reference:

Show entries

Search:

ID	Source
XRA	PDB_CHEM_ID
000635	NDDF
004491	NDDF
19237-84-4	SECONDARY_CAS_RN
203210	RXNORM
2426	MMSL
2593	INN_ID
387283005	SNOMEDCT_US
387433003	SNOMEDCT_US
4018850	VANDF

Showing 1 to 10 of 26 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Minipress	HUMAN PRESCRIPTION DRUG LABEL	1	0069-4310	CAPSULE	1 mg	ORAL	NDA	22 sections
Minipress	HUMAN PRESCRIPTION DRUG LABEL	1	0069-4370	CAPSULE	2 mg	ORAL	NDA	22 sections
Minipress	HUMAN PRESCRIPTION DRUG LABEL	1	0069-4380	CAPSULE	5 mg	ORAL	NDA	22 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4067	CAPSULE	1 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4068	CAPSULE	2 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4069	CAPSULE	5 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1101	CAPSULE	1 mg	ORAL	ANDA	22 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1101	CAPSULE	1 mg	ORAL	ANDA	22 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1101	CAPSULE	1 mg	ORAL	ANDA	22 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-2302	CAPSULE	2 mg	ORAL	ANDA	22 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next